Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

INZ 701

Next Previous
Drug Profile

INZ 701

Alternative Names: INZ-701; rhENPP1-Fc

Latest Information Update: 14 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Inozyme Pharma
  • Class Enzymes; Immunoglobulin Fc fragments; Recombinant fusion proteins
  • Mechanism of Action Ectonucleotide pyrophosphatase phosphodiesterase 1 replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Calcinosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Calcinosis
  • Phase I/II Pseudoxanthoma elasticum; X-linked dominant hypophosphataemic rickets
  • Phase I Calciphylaxis
  • Research Unspecified

Most Recent Events

  • 08 Apr 2024 Efficacy, safety, pharmacodynamics and Immunogenicity data from a phase I/II trial in Calcinosis released by Inozyme Pharma
  • 08 Apr 2024 Inozyme Pharma plans the pivotal trial for Calcinosis (In infants, In children) in USA and Europe
  • 12 Mar 2024 Inozyme Pharma plans the ENERGY-2 pivotal trial for Calcinosis (ENPP1 Deficiency) (In infants, In neonates) ex-USA in the second half of 2024 (SC, Injection)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top